Last reviewed · How we verify

NCT03732612: REBEL

Inflammation in Vascular Disease

Recruiting now Last updated 6 May 2025
What this trial tests

trial in Vascular Diseases in 170 participants. Currently enrolling.

Timeline
2 September 2019
Primary endpoint
1 February 2026
1 February 2027

Quick facts

Lead sponsorGöteborg University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment170
Start date2 September 2019
Primary completion1 February 2026
Estimated completion1 February 2027
Sites1 location across Sweden

Conditions studied

Sponsor

Göteborg University

Who can join

18 and older, any sex, with Vascular Diseases or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Increasing evidence suggests that systemic low-grade inflammation may be a driving force of cardiometabolic complications, such as vascular dysfunction, atherosclerosis and ischemic heart disease. Thus, we will investigate the role of inflammation in cardiovascular disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis.
    Kraft JD, Blomgran R, Bergström I, Soták M, et al · · 2022 · cited 17× · PMID 35104001 · DOI 10.1096/fj.202101219rr

Verify or expand the search:

Other recruiting trials for Vascular Diseases

Currently open trials in the same condition.

Other Göteborg University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing